Cone cornea is a corneal lesion characterized by dilatation of the cornea, resulting in a forward projection of the central part of the cornea, thinning to a conical shape and producing a high degree of irregular astigmatism. Cone keratoconus is a common disease with an incidence of about 1 in 2000, mostly developing slowly during adolescence. Traditional treatment options for conical corneas include: corneal stromal ring implantation, corneal deep lamellar transplantation or penetrating corneal transplantation, and RGP lenses, all of which are methods to improve the biomechanical strength of the cornea and are limited to treating the already diseased cornea and cannot address the underlying defects within the cornea. Corneal collagen cross link-ing (CXL) is a treatment that mechanizes the cornea, increases corneal stiffness and structural integrity, and prevents the disease from progressing to its final stage. Riboflavin/UV ( 370 nm) corneal collagen cross-linking is a new treatment method and the first treatment option that can effectively control cone cornea progression and corneal dilatation after LASIK. Our ophthalmology hospital was the first in the province to introduce the KXL system from Avedro USA to accelerate the collagen crosslinking technique to just a few minutes by increasing the UVA (ultraviolet) energy and decreasing the exposure time of the same energy on the patient’s eye during collagen crosslinking. Thus the high energy of the KXL system shortens the exposure time of UVA, thus increasing the safety and comfort of the patient while greatly improving the efficiency of the procedure.